Contrast Induced Nephropathy News and Research

RSS

Contrast-induced nephropathy (CIN) is a common complication of radiographic procedures and is the third leading cause of hospital aquired renal failure. It is associated with significant morbidity and mortality.

Inorganic nitrate reduces contrast-induced nephropathy in high-risk patients

Inorganic nitrate reduces contrast-induced nephropathy (CIN), improves renal outcomes and reduces cardiac events compared to placebo in patients at risk of renal injury undergoing coronary angiography for acute coronary syndrome, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

29 Aug 2023

Study shows efficacy and safety of OCT-guided strategy for percutaneous coronary intervention

Optical coherence tomography (OCT) is non-inferior to intravascular ultrasound (IVUS) for guiding percutaneous coronary intervention (PCI), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

28 Aug 2023

Beetroot may reduce kidney failure risk after heart x-ray, research reveals

Beetroot may reduce the risk of kidney failure in patients having a heart x-ray, according to research led by Queen Mary University of London.

22 Feb 2018

Intravenous contrast media used in CT not linked to increased risk of acute kidney injury

Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography does not appear to be associated with chronic kidney disease, dialysis, kidney transplant or acute kidney injury, despite long-held fears to the contrary.

27 Jan 2017

Simple diagnostic algorithm to assess pulmonary embolism risk can help reduce rate of CTPA imaging

Patients with suspected pulmonary embolism (PE) often undergo computed tomography pulmonary angiography (CTPA) to confirm or exclude the diagnosis.

31 Aug 2016

New iodine-based contrast material enhances CT images to safely use in most patients

According to new research performed at the Mayo Clinic, iodine-based contrast material injected intravenously to enhance computed tomography (CT) images can be safely used in most patients. The study appears online in the journal Radiology.

9 Sep 2014

Complete revascularisation leads to better outcomes in patients with heart attack

In patients being treated for heart attack, complete revascularisation of all significantly blocked arteries leads to better outcomes compared to a strategy of unblocking just the "culprit" artery responsible for the heart attack, according to a new study presented today at ESC Congress 2014.

1 Sep 2014

Dye reduction in diagnostic heart procedures: an interview with Mike McCormick, CEO Osprey Medical

Iodine based contrast media (dye) is radiopaque and is commonly used for diagnostic and interventional heart procedures. It allows physicians to see real time images of the heart vessels and treat any blockages.

3 Dec 2013

Preventive PCI for patients with ST elevation myocardial infarction results in better outcomes

Heart attack patients with ST elevation who undergo a preventive procedure to unblock additional coronary arteries have significantly better outcomes than those whose treatment is confined to the culprit blockage only, according to the results of the Preventive Angioplasty in Myocardial Infarction (PRAMI) Trial

5 Sep 2013

LVEDP-guided hydration effectively prevents CI-AKI in patients undergoing cardiac catheterization

A hydration regimen tailored to the patient's fluid status was effective in reducing damage to kidneys in patients undergoing cardiac catheterization, according to a study presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

26 Oct 2012

Osprey Medical closes IPO raising of A$20 million

Osprey Medical Inc, has today announced that its Initial Public Offer (IPO) raising of A$20 million has closed. Osprey Medical’s Offer was well supported by institutional and retail investors in Australia, including founding investors CM Capital and Brandon Capital. The Initial Public Offer was underwritten by Shaw Corporate Finance.

17 Apr 2012

PLC Systems fourth quarter total revenues increase to $189,000

PLC Systems Inc., a company focused on innovative medical device technologies, today reported financial results for the three- and twelve month periods ended December 31, 2011.

31 Mar 2012

PLC receives Brazilian government approval to market RenalGuard System

PLC Systems Inc., a company focused on innovative medical device technologies, today announced that it had received approval from the Brazilian government to market its innovative RenalGuard System in that country.

31 Mar 2012

Exposure to iodinated contrast media may increase risk of hyperthyroidism

Exposure to iodinated contrast media during imaging procedures is associated with changes in thyroid function, and increased risk of developing hyperthyroidism, according to a report in the January 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

24 Jan 2012

PLC Systems initiates enrollment in RenalGuard pivotal trial for CIN

PLC Systems Inc., a company focused on innovative medical device technologies, announced the successful enrollment of the first patient in the CIN-RG trial, the company's pivotal trial to study the efficacy of its RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy.

24 Jan 2012

MYTHOS clinical trial demonstrates superiority of RenalGuard in reducing CIN

PLC Systems Inc., a company focused on innovative medical device technologies, today announced that final results from the MYTHOS investigator-sponsored clinical trial of RenalGuard in Italy have been published in the January 2012 issue of JACC – Cardiovascular Interventions, a peer-reviewed journal of the American College of Cardiology.

13 Jan 2012

FDA approves PLC's U.S. pivotal trial of RenalGuard to prevent Contrast-Induced Nephropathy

PLC Systems Inc., a company focused on innovative medical device technologies, announced today that it has received final approval from the U.S. Food and Drug Administration to commence its U.S. pivotal trial to study the efficacy of the Company's RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy.

14 Oct 2011

PLC Systems second quarter total revenues increase to $398,000

PLC Systems Inc., a company focused on innovative medical device technologies, today reported financial results for the three- and six month periods ended June 30, 2011. These results only include the company's RenalGuard® operations, since PLC completed the sale of its transmyocardial revascularization (TMR) business to Novadaq Corp. during the first quarter of 2011.

12 Aug 2011

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced it successfully completed patient enrollment in its phase II Contrast-Induced Acute Kidney Injury study with its oral drug candidate CRMD001.

14 Jun 2011

PLC Systems to showcase RenalGuard at 2011 EAPCI annual meeting

PLC Systems Inc., a company focused on innovative medical device technologies, today announced it will demonstrate its innovative new product, RenalGuard, at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions.

12 May 2011